BFRI Biofrontera Inc

USD 1.54 0.39 33.913043
Icon

Biofrontera Inc (BFRI) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.54

+0.39 (+33.91)%

USD 8.91M

0.25M

N/A

USD 0.00 (-100.00%)

Icon

BFRI

Biofrontera Inc (USD)
COMMON STOCK | NSD
USD 1.54
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 8.91M

USD 0.00 (-100.00%)

USD 1.54

Biofrontera Inc (BFRI) Stock Forecast

N/A

Based on the Biofrontera Inc stock forecast from 0 analysts, the average analyst target price for Biofrontera Inc is not available over the next 12 months. Biofrontera Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biofrontera Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Biofrontera Inc’s stock price was USD 1.54. Biofrontera Inc’s stock price has changed by +23.20% over the past week, +89.42% over the past month and -86.73% over the last year.

No recent analyst target price found for Biofrontera Inc
No recent average analyst rating found for Biofrontera Inc

Company Overview Biofrontera Inc

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, ...Read More

120 Presidential Way, Woburn, MA, United States, 01801

81

December

USD

USA

Adjusted Closing Price for Biofrontera Inc (BFRI)

Loading...

Unadjusted Closing Price for Biofrontera Inc (BFRI)

Loading...

Share Trading Volume for Biofrontera Inc Shares

Loading...

Compare Performance of Biofrontera Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BFRI

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Biofrontera Inc (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS
Zoetis Inc +0.70 (+0.42%) USD79.01B 34.04 22.84

ETFs Containing BFRI

Symbol Name BFRI's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Biofrontera Inc (BFRI) Stock

Stock Target Advisor's fundamental analysis for Biofrontera Inc's stock is Very Bearish.

Unfortunately we do not have enough data on BFRI's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BFRI's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on BFRI's stock to indicate if its overvalued.

The last closing price of BFRI's stock was USD 1.54.

The most recent market capitalization for BFRI is USD 8.91M.

Unfortunately we do not have enough analyst data on BFRI's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Biofrontera Inc's stock.

As per our most recent records Biofrontera Inc has 81 Employees.

Biofrontera Inc's registered address is 120 Presidential Way, Woburn, MA, United States, 01801. You can get more information about it from Biofrontera Inc's website at https://www.biofrontera-us.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...